Report Details
Introduction
- Accelerating Demand for On-the-Spot Diagnostics: The global point-of-care biopsy market, valued at approximately USD 3.4 billion in 2024, is witnessing a surge in demand due to the rising preference for rapid, minimally invasive diagnostic procedures across hospitals, clinics, and ambulatory settings.
- Robust Growth Driven by Technological Advancements: With the integration of advanced imaging technologies and portable biopsy tools, the market is projected to nearly double—reaching close to USD 6.6 billion by 2032—reflecting a strong CAGR of 14.3% from 2024 to 2032.
- Shifting Healthcare Landscape and Rising Cancer Prevalence: The increasing global incidence of cancer and the emphasis on early, decentralized diagnosis are key drivers accelerating the adoption of point-of-care biopsy solutions across both developed and emerging economies.
Porter’s Five Forces Analysis – Global Point-of-Care Biopsy Market
- Threat of New Entrants: Moderate to High due to increasing interest in portable diagnostics and growing healthcare investments. However, regulatory barriers, R&D intensity, and clinical validation requirements limit easy entry for new players.
- Bargaining Power of Suppliers: Moderate, as specialized components and advanced imaging technologies are often sourced from niche suppliers. Suppliers with patented technologies or exclusive material sources hold stronger leverage.
- Bargaining Power of Buyers: Increasing, especially with rising awareness and availability of alternative diagnostic methods. Large hospital networks and procurement groups demand cost-effective and clinically proven solutions.
- Threat of Substitutes: Moderate, with alternatives such as traditional biopsies, imaging-only diagnostics, and liquid biopsies gaining traction. However, point-of-care biopsies offer unmatched advantages in speed and on-site accuracy, maintaining their relevance.
- Industry Rivalry: High, as established med-tech giants and innovative startups compete for market share through product differentiation, AI integration, and geographic expansion. Frequent technological upgrades and price competition intensify rivalry across global and regional markets.
Market Overview & Segmentation: Global Point-of-Care Biopsy Market
1. By Product Type
1.1 Needle-Based Biopsy Instruments
1.2 Vacuum-Assisted Biopsy Systems
1.3 Core Needle Biopsy Devices
1.4 Fine Needle Aspiration (FNA) Devices
1.5 Surgical Biopsy Equipment
1.6 Disposable Biopsy Tools
1.7 Reusable Biopsy Tools
2. By Technique
2.1 Image-Guided Biopsy
2.2 Stereotactic Biopsy
2.3 Ultrasound-Guided Biopsy
2.4 MRI-Guided Biopsy
2.5 CT-Guided Biopsy
2.6 Non-Guided Manual Techniques
3. By Application
3.1 Breast Cancer
3.2 Lung Cancer
3.3 Prostate Cancer
3.4 Colorectal Cancer
3.5 Skin Cancer
3.6 Other Cancer Types
4. By End-Use
4.1 Hospitals
4.2 Diagnostic Laboratories
4.3 Ambulatory Surgical Centers (ASCs)
4.4 Specialty Clinics
4.5 Homecare Settings
4.6 Research & Academic Institutes
5. By Region
5.1 North America
5.1.1 United States
5.1.2 Canada
5.2 Europe
5.2.1 Germany
5.2.2 United Kingdom
5.2.3 France
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest of Europe
5.3 Asia-Pacific
5.3.1 China
5.3.2 Japan
5.3.3 India
5.3.4 South Korea
5.3.5 Australia
5.3.6 Rest of Asia-Pacific
5.4 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Argentina
5.4.4 Rest of Latin America
5.5 Middle East & Africa
5.5.1 GCC Countries
5.5.2 South Africa
5.5.3 Rest of MEA
6. Key Players in Global Point-of-Care Biopsy Market
6.1 BD (Becton, Dickinson and Company)
6.2 Danaher Corporation (Leica Biosystems)
6.3 Hologic, Inc.
6.4 Argon Medical Devices, Inc.
6.5 INRAD, Inc.
6.6 Cardinal Health, Inc.
6.7 Cook Medical LLC
6.8 Devicor Medical Products, Inc. (Part of Leica Biosystems)
6.9 Boston Scientific Corporation
6.10 Medtronic plc
6.11 Scion Medical Technologies, LLC
6.12 C.R. Bard, Inc. (Now part of BD)
6.13 Zamar Care
6.14 Bioncise
6.15 Stryker Corporation
6.16 Others
Table of Contents (TOC)
1. Executive Summary
2. Research Methodology
3. Market Overview
3.1 Introduction
3.2 Market Definition and Scope
3.3 Industry Ecosystem Analysis
3.4 Market Dynamics
3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities
3.4.4 Challenges
4. Impact of COVID-19 on Point-of-Care Biopsy Market
5. Point-of-Care Biopsy Market – Porter’s Five Forces Analysis
6. Global Point-of-Care Biopsy Market Analysis and Forecast (2017–2033)
7. Market Segmentation
7.1 By Product Type
7.1.1 Needle-Based Biopsy Instruments
7.1.2 Vacuum-Assisted Biopsy Systems
7.1.3 Core Needle Biopsy Devices
7.1.4 Fine Needle Aspiration (FNA) Devices
7.1.5 Surgical Biopsy Equipment
7.1.6 Disposable Biopsy Tools
7.1.7 Reusable Biopsy Tools
7.2 By Technique
7.2.1 Image-Guided Biopsy
7.2.2 Stereotactic Biopsy
7.2.3 Ultrasound-Guided Biopsy
7.2.4 MRI-Guided Biopsy
7.2.5 CT-Guided Biopsy
7.2.6 Non-Guided Manual Techniques
7.3 By Application
7.3.1 Breast Cancer
7.3.2 Lung Cancer
7.3.3 Prostate Cancer
7.3.4 Colorectal Cancer
7.3.5 Skin Cancer
7.3.6 Other Cancer Types
7.4 By End-Use
7.4.1 Hospitals
7.4.2 Diagnostic Laboratories
7.4.3 Ambulatory Surgical Centers (ASCs)
7.4.4 Specialty Clinics
7.4.5 Homecare Settings
7.4.6 Research & Academic Institutes
8. Regional Analysis
8.1 North America
8.1.1 United States
8.1.2 Canada
8.2 Europe
8.2.1 Germany
8.2.2 United Kingdom
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 South Korea
8.3.5 Australia
8.3.6 Rest of Asia-Pacific
8.4 Latin America
8.4.1 Brazil
8.4.2 Mexico
8.4.3 Argentina
8.4.4 Rest of Latin America
8.5 Middle East & Africa
8.5.1 GCC Countries
8.5.2 South Africa
8.5.3 Rest of MEA
9. Competitive Landscape
9.1 Overview of Key Players
9.2 Company Market Share Analysis
9.3 Strategic Developments
10. Key Players Profiled
10.1 BD (Becton, Dickinson and Company)
10.2 Danaher Corporation (Leica Biosystems)
10.3 Hologic, Inc.
10.4 Argon Medical Devices, Inc.
10.5 INRAD, Inc.
10.6 Cardinal Health, Inc.
10.7 Cook Medical LLC
10.8 Devicor Medical Products, Inc. (Part of Leica Biosystems)
10.9 Boston Scientific Corporation
10.10 Medtronic plc
10.11 Scion Medical Technologies, LLC
10.12 C.R. Bard, Inc. (Now part of BD)
10.13 Zamar Care
10.14 Bioncise
10.15 Stryker Corporation
11. Conclusion & Future Outlook
12. Appendix
12.1 Data Sources
12.2 Glossary of Terms
12.3 Abbreviations
Market Overview & Segmentation: Global Point-of-Care Biopsy Market
1. By Product Type
1.1 Needle-Based Biopsy Instruments
1.2 Vacuum-Assisted Biopsy Systems
1.3 Core Needle Biopsy Devices
1.4 Fine Needle Aspiration (FNA) Devices
1.5 Surgical Biopsy Equipment
1.6 Disposable Biopsy Tools
1.7 Reusable Biopsy Tools
2. By Technique
2.1 Image-Guided Biopsy
2.2 Stereotactic Biopsy
2.3 Ultrasound-Guided Biopsy
2.4 MRI-Guided Biopsy
2.5 CT-Guided Biopsy
2.6 Non-Guided Manual Techniques
3. By Application
3.1 Breast Cancer
3.2 Lung Cancer
3.3 Prostate Cancer
3.4 Colorectal Cancer
3.5 Skin Cancer
3.6 Other Cancer Types
4. By End-Use
4.1 Hospitals
4.2 Diagnostic Laboratories
4.3 Ambulatory Surgical Centers (ASCs)
4.4 Specialty Clinics
4.5 Homecare Settings
4.6 Research & Academic Institutes
5. By Region
5.1 North America
5.1.1 United States
5.1.2 Canada
5.2 Europe
5.2.1 Germany
5.2.2 United Kingdom
5.2.3 France
5.2.4 Italy
5.2.5 Spain
5.2.6 Rest of Europe
5.3 Asia-Pacific
5.3.1 China
5.3.2 Japan
5.3.3 India
5.3.4 South Korea
5.3.5 Australia
5.3.6 Rest of Asia-Pacific
5.4 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Argentina
5.4.4 Rest of Latin America
5.5 Middle East & Africa
5.5.1 GCC Countries
5.5.2 South Africa
5.5.3 Rest of MEA
6. Key Players in Global Point-of-Care Biopsy Market
6.1 BD (Becton, Dickinson and Company)
6.2 Danaher Corporation (Leica Biosystems)
6.3 Hologic, Inc.
6.4 Argon Medical Devices, Inc.
6.5 INRAD, Inc.
6.6 Cardinal Health, Inc.
6.7 Cook Medical LLC
6.8 Devicor Medical Products, Inc. (Part of Leica Biosystems)
6.9 Boston Scientific Corporation
6.10 Medtronic plc
6.11 Scion Medical Technologies, LLC
6.12 C.R. Bard, Inc. (Now part of BD)
6.13 Zamar Care
6.14 Bioncise
6.15 Stryker Corporation
6.16 Others
Please fill this form
Frequently Asked Questions
What’s driving the boom in point-of-care biopsy tools, and how is cancer detection transforming in real time?
The rise in minimally invasive diagnostics, real-time cancer detection, and growing demand for faster results in outpatient settings are revolutionizing the biopsy space. Advanced point-of-care biopsy tools now empower physicians to diagnose conditions instantly—right at the bedside or in remote clinics—cutting down wait times and improving survival outcomes.
How are AI and imaging integration redefining point-of-care biopsy procedures globally?
AI-enhanced imaging and smart-guided biopsy devices are enabling ultra-precise targeting of suspicious tissues. These innovations are transforming how clinicians perform real-time biopsies, especially in breast, lung, and prostate cancer diagnostics, helping reduce false negatives and increasing diagnostic confidence.
Which regions are becoming biopsy innovation hubs, and why is Asia-Pacific leading the charge?
Asia-Pacific, particularly China, India, and Japan, is witnessing explosive growth due to rising cancer prevalence, government initiatives for early screening, and rapid adoption of portable diagnostic tech. The region's affordability-focused innovations are also pushing point-of-care biopsy into emerging rural markets.
What makes vacuum-assisted and image-guided biopsies game-changers in outpatient and homecare settings?
Vacuum-assisted and image-guided biopsy systems provide high tissue yield with minimal discomfort, making them ideal for ambulatory surgical centers and even homecare environments. These techniques enable physicians to conduct procedures with higher accuracy and faster recovery, reshaping patient-centered cancer diagnostics.
Which companies are setting new benchmarks in the point-of-care biopsy space, and what are they innovating next?
Leaders like BD, Hologic, Medtronic, and Leica Biosystems are pushing boundaries with AI-driven biopsy systems, ultra-portable devices, and integration with digital pathology platforms. The next wave includes smart biopsy tools with cloud connectivity, enabling remote diagnostics and real-time collaboration between global specialists.